

Please try another search
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled solution via ultrasonic nebulizer; Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Remunity Pump, a small, lightweight, durable pump and separate controller; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and TETON studies, which are the studies of Tyvaso for the treatment of idiopathic pulmonary fibrosis. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Name | Age | Since | Title |
---|---|---|---|
Thomas G. Thompson | 79 | 2010 | Independent Director |
Samuel O. Thier | 83 | - | Member of the Scientific Advisory Board |
Robert C. Bourge | - | - | Member of the Scientific Advisory Board |
Christopher Patusky | 57 | 2002 | Independent Vice Chairman & Lead Independent Director |
Linda Maxwell | 47 | 2020 | Independent Director |
Richard Giltner | 57 | 2009 | Independent Director |
Raymond C. Kurzweil | 73 | 2002 | Independent Director |
Raymond A. Dwek | 79 | 2002 | Independent Director & Member of the Scientific Advisory Board |
Louis W. Sullivan | 88 | 2002 | Independent Director & Member of the Scientific Advisory Board |
Christopher Causey | 58 | 2003 | Independent Director |
Nilda Mesa | 61 | 2018 | Independent Director |
Martine A. Rothblatt | 66 | 1996 | Founder, Chairman & CEO |
Mardi Gomberg-Maitland | - | - | Member of The Scientific Advisory Board |
Magdi H. Yacoub | 85 | - | Member of The Scientific Advisory Board |
Katherine J. Klein | 64 | 2014 | Independent Director |
Judy D. Olian | 69 | 2015 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review